Idiopathic Pulmonary Fibrosis

View All

Pharma News for Pfizer, Sarepta, FibroGen, Erasca
FDA Approves Jardiance for Type 2 Diabetes; FDA Approves Pfizer’s LITFULO for Alopecia Areata; Sarepta Therapeutics’s ELEVIDYS Approval; Tonix Pharmaceuticals to Acquire Two Migraine Products from Upsher-Smith; FibroGen’s Phase 3 ZEPHYRUS-1 Study of Pamrevlumab; FDA Orphan Drug Designation to ERAS-801 for Malignant Glioma

FDA Approves Jardiance for the Treatment of Type 2 Diabetes in Children 10 Years and Older Boehringer Ingelheim and Eli Lilly and Company announced that the FDA has approved Jardiance® (empagliflozin) 10 mg and 25 mg tablets to decrease blood sugar together with diet and exercise in children 10 years and older w...

Find More

Pharma News for Actinium, Santhera, Gilead, Seres, BMS, Boehringer
Actinium Announces SIERRA Trial Results; Santhera Seeks FDA Review for Vamorolone; Seres Announces BLA Submission for SER-109; BMS Announces Results of COMMANDS Trial; Boehringer’s PDE4B Moves Late-stage Clinical Testing; FDA Rejects Gilead’s Hepcludex; Approval to J&J’s BCMAxCD3 Bispecific Antibody for Multiple Myeloma; Syncona to Acquire AGTC

Actinium Announces Positive Top-line Results from Pivotal Phase III SIERRA Trial of Iomab-B Actinium Pharma is on track to submit its targeted radiotherapy for AML patients requiring a bone marrow transplant in the United States, boosted by top-line data from a pivotal trial. The SIERRA trial of Iomab-B, an anti...

Find More

Pharma News Updates for Sumitomo, AstraZeneca, and AbbVie
Sumitomo to Purchase Myovant; AstraZeneca’s Tremelimumab Plus Imfinzi Approved in the US; AbbVie Acquires DJS Antibodies; Roche and Hookipa Pharma Signs USD 25 Million Deal; FDA Accepts BMS’s New Drug Application for CAMZYOS; Jazz and Zymeworks Sign Exclusive Licencing Agreement

FDA Accepts Bristol Myers Squibb’s Supplemental New Drug Application for CAMZYOS Bristol Myers Squibb declared that the U.S. FDA had accepted its supplemental new drug application for CAMZYOS for an expanded indication to reduce the need for septal reduction therapy. CAMYZOS is currently FDA-approved for treatin...

Find More

PDE4-B Inhibitors: A Promising Target for Idiopathic Pulmonary Fibrosis Treatment

Idiopathic pulmonary fibrosis (IPF) is a rare, sporadic, and fatal interstitial lung disease. As the morbidity and mortality rates associated with IPF remain high, prompt idiopathic pulmonary fibrosis treatment is critical to safeguard individuals’ lung function, reduce the risk of acute exacerbations, and improve ...

Find More

Pharma News and Analysis for BMS, Sandoz, and Pfizer
BMS Sells NY Biologics Plant; FDA Approves Mitsubishi Tanabe’s Radicava, Love Pharma Acquires MicroDoz; Sandoz Launches Generic of Roche’s Esbriet; Pfizer to Acquire Biohaven Pharma; eureKARE’s Cell and Gene Therapy CDMO; Atamyo’s LGMD Gene Therapies; FDA approves Eli Lilly’s Type 2 Diabetes Treatment

Love Pharma Completes the Acquisition of MicroDoz Therapy LOVE Pharma Co. has announced the completion of its acquisition of MicroDoz Theraphy Inc. ("MicroDoz"). Love Pharma holds exclusive manufacturing, marketing, packaging, selling, and distribution licenses in Europe, the United Kingdom, and North America. U...

Find More

Pharma News and Updates for Coherus, Keymed, Roche, Vicore, Cassiopea
Coherus Biosciences’ Toripalimab; Keymed’s CMG901; Biogen Alzheimer’s Drug Aduhelm; Vicore’s Digital Therapeutics Study; Cassiopea’s Acne Treatment Winlevi; Samsung Biologics Acquires Samsung Bioepis; Roche’s Giredestrant; Ashai Kasei Acquires Bionova

FDA Grants Orphan Drug Designation to Coherus Biosciences’ Toripalimab for Small Cell Lung Cancer The FDA granted orphan drug status to Coherus Biosciences’ Toripalimab (TuoYi) based on data from the phase 3 JUPITER-08 study in patients with extensive-stage Small-cell Lung Cancer (ES-SCLC). Patients in the curre...

Find More

pharma-news-for-algernon-pieris-gaumard-hekka-labs
Algernon’s NP-120 (ifenprodil); Pieris’s cinrebafusp alfa (PRS-343) clinical trial; Gaumard Scientific’s multidisciplinary patient simulator HAL S5301; Hekka Labs’s decentralized healthcare ecosystem

Algernon receives positive FDA feedback on Phase IIb chronic cough trial The US Food and Drug Administration (FDA) has given positive feedback for Algernon Pharmaceuticals’ Phase IIb clinical trial of NP-120 (ifenprodil) for chronic cough treatment.  A receptor antagonist of N-methyl-D-aspartate (NMDA), ifenp...

Find More

pharma news
Ofev’s expanded use; Arkin Bio-Ventures II launch; USD 125 M for COVID-19 treatment

Boehringer Ingelheim’s Ofev (nintedanib) has received FDA recommendation for the treatment of chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype Interstitial Lung Disease - ILD – a group of a large number of lung disorders resulting in scarring or fibrosis of lungs, caused by conditi...

Find More

Idiopathic Pulmonary Fibrosis Market Landscape and Forecast
Idiopathic Pulmonary Fibrosis Market Landscape and Forecast

According to NIH, Idiopathic Pulmonary Fibrosis prevalent cases are estimated to be 13 to 20 per 100,000 people worldwide, making it’s a rare but severe lung disease.Idiopathic Pulmonary Fibrosis (IPF) is progressive and chronic scarring of lung tissues hampering the transport of the oxygen into the bloodstream. T...

Find More

idiopathic-pulmonary-fibrosis-scarring-for-a-lifetime
Idiopathic Pulmonary Fibrosis –Scarring For A Lifetime

Sometimes, something gets missed from our eyes; often, our ignorance delays the diagnosis of something fatal. Idiopathic Pulmonary fibrosis is a chronic, rare, progressive fibrosing interstitial pneumonia. It is a harsh condition that scars the lung tissues for a lifetime and hampers the normal functioning of th...

Find More